Denver Investment Advisors LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,454 shares of the medical instruments supplier’s stock after selling 16 shares during the period. Denver Investment Advisors LLC’s holdings in Becton, Dickinson and were worth $2,040,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BDX. North Star Investment Management Corp. lifted its stake in Becton, Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares during the last quarter. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and in the 1st quarter valued at approximately $105,000. Parkside Financial Bank & Trust lifted its stake in Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 9 shares during the last quarter. QCI Asset Management Inc. NY lifted its stake in Becton, Dickinson and by 9.2% in the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 60 shares during the last quarter. Finally, Financial Architects Inc lifted its stake in Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

BDX has been the subject of several research reports. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the company from $210.00 to $180.00 in a research note on Friday, June 30th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, July 17th. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday. Finally, BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $196.93.

ILLEGAL ACTIVITY WARNING: “Denver Investment Advisors LLC Has $2.04 Million Position in Becton, Dickinson and Company (BDX)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/15/denver-investment-advisors-llc-has-2-04-million-position-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company (NYSE BDX) opened at 197.58 on Friday. The stock’s 50 day moving average is $199.61 and its 200 day moving average is $191.24. The company has a market cap of $44.96 billion, a P/E ratio of 57.22 and a beta of 1.06. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the prior year, the company earned $2.35 EPS. The firm’s revenue was down 5.1% on a year-over-year basis. Equities analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Linda M. Tharby sold 4,695 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the completion of the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock valued at $15,242,688 in the last ninety days. 1.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.